← Back to Analyst Consensus 
CTMX Buy
CytomX Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 13, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Aug 10, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 23, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Mar 19, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Mar 18, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Mar 18, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 17, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Mar 16, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 16, 2026 | JP Morgan | upgrade | Neutral → Overweight | — | 54% |
| Mar 9, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Feb 4, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | $10 | 50% |
| Feb 4, 2026 | Barclays | maintain | Overweight → Overweight | $10 | 53% |
| Jan 20, 2026 | Barclays | maintain | Overweight → Overweight | $8 | 53% |
| Jan 20, 2026 | Guggenheim | initiate | — → Buy | $10 | 52% |
| Jan 20, 2026 | Piper Sandler | maintain | Overweight → Overweight | $10 | 54% |
| Nov 11, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Oct 21, 2025 | Barclays | maintain | Overweight → Overweight | $6 | 53% |
| Sep 22, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $6 | 50% |
| Jul 31, 2025 | Oppenheimer | initiate | — → Outperform | $7 | 52% |
| May 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| May 15, 2025 | Piper Sandler | maintain | Overweight → Overweight | $5 | 54% |
| May 15, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $5 | 44% |
| Apr 14, 2025 | Piper Sandler | maintain | Overweight → Overweight | $2.5 | 54% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Jan 7, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Sep 13, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Aug 22, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Jun 27, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| May 28, 2024 | Piper Sandler | upgrade | Neutral → Overweight | $3.5 | 54% |
| May 9, 2024 | BMO Capital | maintain | Market Perform → Market Perform | $3.59 | 53% |
| May 9, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| May 9, 2024 | Wedbush | upgrade | Neutral → Outperform | $8 | 58% |
| May 6, 2024 | Jefferies | upgrade | Hold → Buy | $8 | 52% |
| May 1, 2024 | BMO Capital | reiterate | Market Perform → Market Perform | $3.25 | 53% |
| Apr 22, 2024 | JP Morgan | upgrade | Underweight → Neutral | $0 | 54% |
| Mar 12, 2024 | BMO Capital | maintain | Market Perform → Market Perform | $3.25 | 53% |
| Mar 12, 2024 | Wedbush | reiterate | Neutral → Neutral | $3 | 58% |
| Nov 9, 2023 | Wedbush | maintain | Neutral → Neutral | $3 | 58% |
| Nov 8, 2023 | Wedbush | upgrade | Neutral → Outperform | $3 | 58% |
| Aug 9, 2023 | BMO Capital | maintain | Market Perform → Market Perform | $3.19 | 53% |
| Mar 28, 2023 | Mizuho | maintain | — → Neutral | $2 | 52% |
| Jan 6, 2023 | BMO Capital | maintain | — → Market Perform | $3.2 | 53% |
| Nov 14, 2022 | BMO Capital | downgrade | Outperform → Market Perform | $2.6 | 53% |
| Nov 10, 2022 | JP Morgan | downgrade | Overweight → Underweight | $0 | 54% |
| Jul 11, 2022 | Cowen & Co. | downgrade | Outperform → Market Perform | $0 | — |
| Jul 11, 2022 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Jul 7, 2022 | Jefferies | downgrade | Buy → Hold | $2 | 52% |
| Jul 7, 2022 | BMO Capital | maintain | — → Outperform | $3 | 53% |
Price Target Trend
Jun 30, 2026 Oct 26, 2026
EPS Estimates
+1y —
+1q —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days